105
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Second Primary Malignancy in Patients with Hypopharyngeal Carcinoma: A SEER-Based Study

ORCID Icon, , , , &
Pages 8847-8861 | Published online: 25 Nov 2021

Reference

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
  • Kwon DI, Miles BA. Hypopharyngeal carcinoma: do you know your guidelines? Head Neck. 2019;41(3):569–576. doi:10.1002/hed.24752
  • Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2016;91(3):386–396. doi:10.1016/j.mayocp.2015.12.017
  • Tassler AB, Gooding WE, Ferris RL. Hypopharyngeal cancer treatment: does initial surgery confer survival benefit? Head Neck. 2019;41(7):2167–2173. doi:10.1002/hed.25687
  • Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16(11):669–683. doi:10.1038/s41571-019-0227-z
  • Huang S, Yang J, Fong S, Zhao Q. Artificial intelligence in cancer diagnosis and prognosis: opportunities and challenges. Cancer Lett. 2020;471:61–71. doi:10.1016/j.canlet.2019.12.007
  • Schoots IG, Padhani AR. Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated? World J Urol. 2020;38(3):531–545. doi:10.1007/s00345-019-02899-0
  • Wang W. Increased incidence of second primary malignancy in patients with malignant astrocytoma: a population-based study. Biosci Rep. 2019;39(6):Jun. doi:10.1042/BSR20181968
  • Davis EJ, Beebe-Dimmer JL, Yee CL, Cooney KA. Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study. Cancer. 2014;120(17):2735–2741. doi:10.1002/cncr.28769
  • Lee DH, Roh JL, Baek S, et al. Second cancer incidence, risk factor, and specific mortality in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2013;149(4):579–586. doi:10.1177/01945998134963.73
  • Baxi SS, Pinheiro LC, Patil SM, Pfister DG, Oeffinger KC, Elkin EB. Causes of death in long-term survivors of head and neck cancer. Cancer. 2014;120(10):1507–1513. doi:10.1002/cncr.28588
  • Smits HJG, Assili S, Kauw F, Philippens MEP, de Bree R, Dankbaar JW. Prognostic imaging variables for recurrent laryngeal and hypopharyngeal carcinoma treated with primary chemoradiotherapy: a systematic review and meta-analysis. Head Neck. 2021;43(7):2202–2215. doi:10.1002/hed.26698
  • Keegan THM, Bleyer A, Rosenberg AS, Li Q, Goldfarb M. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors. JAMA Oncol. 2017;3(11):1554–1557. doi:10.1001/jamaoncol.2017.0465
  • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi:10.3322/caac.21166
  • Cowens-Alvarado R, Sharpe K, Pratt-Chapman M, et al. Advancing survivorship care through the National Cancer Survivorship Resource Center: developing American Cancer Society guidelines for primary care providers. CA Cancer J Clin. 2013;63(3):147–150. doi:10.3322/caac.21183
  • Khanal A, Budhathoki N, Singh VP, Shah BK. Second primary malignancy in bladder carcinoma - A Population-based Study. Anticancer Res. 2017;37(4):2033–2036. doi:10.21873/anticanres.11548
  • Liang F, Zhang S, Xue H, Chen Q. Risk of second primary cancers in cancer patients treated with cisplatin: a systematic review and meta-analysis of randomized studies. BMC Cancer. 2017;17(1):871. doi:10.1186/s12885-017-3902-4
  • Fleury I, Chevret S, Pfreundschuh M, et al. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Ann Oncol. 2016;27(3):390–397. doi:10.1093/annonc/mdv616
  • Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–e180. doi:10.1016/s1470-2045(14)71116-7
  • Necchi A, Sonpavde G, Lo Vullo S, et al. Nomogram-based prediction of overall survival in patients with metastatic urothelial carcinoma receiving first-line platinum-based chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Eur Urol. 2017;71(2):281–289. doi:10.1016/j.eururo.2016.09.042
  • Pan JJ, Ng WT, Zong JF, et al. Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer. 2016;122(21):3307–3315. doi:10.1002/cncr.30198
  • Ali AN, Switchenko JM, Kim S, Kowalski J, El-Deiry MW, Beitler JJ. A model and nomogram to predict tumor site origin for squamous cell cancer confined to cervical lymph nodes. Cancer. 2014;120(22):3469–3476. doi:10.1002/cncr.28901
  • Shen W, Sakamoto N, Yang L. Cause-specific mortality prediction model for patients with basaloid squamous cell carcinomas of the head and neck: a competing risk analysis. J Cancer. 2018;9(21):4009–4017. doi:10.7150/jca.20274
  • Tang X, Pang T, Yan WF, Qian WL, Gong YL, Yang ZG. A novel prognostic model predicting the long-term cancer-specific survival for patients with hypopharyngeal squamous cell carcinoma. BMC Cancer. 2020;20(1):1095. doi:10.1186/s12885-020-07599-2
  • Tian S, Li Q, Li R, et al. Development and validation of a prognostic nomogram for hypopharyngeal carcinoma. Front Oncol. 2021;11:696952. doi:10.3389/fonc.2021.696952
  • Ndiaye C, Mena M, Alemany L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014;15(12):1319–1331. doi:10.1016/s1470-2045(14)70471-1
  • Kawakita D, Matsuo K. Alcohol and head and neck cancer. Cancer Metastasis Rev. 2017;36(3):425–434. doi:10.1007/s10555-017-9690-0
  • Wookey VB, Appiah AK, Kallam A, Ernani V, Smith LM, Ganti AK. HPV status and survival in non-oropharyngeal squamous cell carcinoma of the head and neck. Anticancer Res. 2019;39(4):1907–1914. doi:10.21873/anticanres.13299
  • Gazdzicka J, Golabek K, Strzelczyk JK, et al. Selected CDKN2A and MDM2 polymorphisms in oral cavity cancer. Acta Biochim Pol. 2020;67(2):213–218. doi:10.18388/abp.2020_5195
  • Misawa K, Mima M, Imai A, et al. The neuropeptide genes SST, TAC1, HCRT, NPY, and GAL are powerful epigenetic biomarkers in head and neck cancer: a site-specific analysis. Clin Epigenetics. 2018;10:52. doi:10.1186/s13148-018-0485-0
  • Rashed WM, Saad AM, Al-Husseini MJ, et al. Incidence of adrenal gland tumor as a second primary malignancy: SEER-based study. Endocr Connect. 2018;7:1040–1048. doi:10.1530/EC-18-0304
  • Abdel-Rahman O. Risk of subsequent primary kidney cancer after another malignancy: a Population-based Study. Clin Genitourin Cancer. 2017;15(5):e747–e754. doi:10.1016/j.clgc.2017.02.004
  • Bezak E, Takam R, Yeoh E, Marcu LG. The risk of second primary cancers due to peripheral photon and neutron doses received during prostate cancer external beam radiation therapy. Phys Med. 2017;42:253–258. doi:10.1016/j.ejmp.2017.02.018
  • Chowdhry AK, Fung C, Chowdhry VK, et al. A population-based study of prognosis and survival in patients with second primary thyroid cancer after Hodgkin lymphoma. Leuk Lymphoma. 2018;59(5):1180–1187. doi:10.1080/10428194.2017.1369063
  • Morais S, Antunes L, Bento MJ, Lunet N. Risk of second primary cancers among patients with a first primary gastric cancer: a population-based study in North Portugal. Cancer Epidemiol. 2017;50:85–91. doi:10.1016/j.canep.2017.08.007
  • Zhuang L, Yan X, Meng Z. Second primary malignancy in patients with cholangiocarcinoma: a population-based study. Cancer Manag Res. 2019;11:1969–1983. doi:10.2147/CMAR.S187614
  • Eckel HE, Bradley PJ. Treatment options for hypopharyngeal cancer. Adv Otorhinolaryngol. 2019;83:47–53. doi:10.1159/000492308
  • Li R, Zhang Y, Ma B, Tan K, Lynn HS, Wu Z. Survival analysis of second primary malignancies after cervical cancer using a competing risk model: implications for prevention and surveillance. Ann Transl Med. 2021;9(3):239. doi:10.21037/atm-20-2003